,143 Many inhibitors of E3 ubiquitin ligases and DUBs have been studied and found to affect the immune response against cancer cells, which in combination with other immunotherapeutic approaches can effectively reduce therapeutic resistance and improve therapeutic efficacy (Table 2).70 The gene discussed is PRKN; the disease is cancer.